GlaxoSmithKline

GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)

16 May 2024

GSK pledges to support the Fleming Initiative - an innovative and collaborative approach to develop new AMR interventions.

16 May 2024

16 May 2024

GSK pledges to support the Fleming Initiative - an innovative and collaborative approach to develop new AMR interventions.

GSK makes a strong start to 2024 with improving outlook for the year

02 May 2024

Q1 2024 performance highlights

01 May 2024

02 May 2024

Q1 2024 performance highlights

US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer

24 Apr 2024

Application supported by statistically significant and clinically meaningful progression-free and overall survival data from RUBY trial

24 April 2024

24 Apr 2024

We are currently updating the site. Full service will resume shortly

EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments

17 Apr 2024

GSK has announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin.

New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade

17 Apr 2024

End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination.

17 April 2024

17 Apr 2024

End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination.

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

16 Apr 2024

Prescription Drug User Fee Act action date set by FDA for 14 February 2025.